Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Yokota, Masako ^a   Kobayashi, Yukiho ^a   Morita, Jumpei ^a   Suzuki, Hiroyuki ^a   Hashimoto, Yoshihide ^c   Sasaki, Yoshihiro ^a,b   Akiyoshi, Kazunari ^a,b,c   Moriyama, Keiji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; CODON; ESRP1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR 2; MACROGOL DERIVATIVE; NANOGEL; POLYETHYLENEIMINE; PROTEIN BINDING; RECOMBINANT PROTEIN; RNA BINDING PROTEIN;

ACROCEPHALOSYNDACTYLY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; DIMERIZATION; EMBRYO; GENE MUTATION; HYDROGEL; IMMUNOPRECIPITATION; MINERALIZATION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; SKULL SUTURE; SYNOSTOSIS; WESTERN BLOTTING; ACROCEPHALOSYNDACTYLIA; AMINO ACID SUBSTITUTION; ANIMAL; BONE MINERALIZATION; CELL LINE; CODON; CONGENITAL MALFORMATION; CRANIAL SUTURE; CYTOLOGY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MUTATION; OSTEOBLAST; PHENOTYPE; TRANSGENIC MOUSE;

ACROCEPHALOSYNDACTYLIA; AMINO ACID SUBSTITUTION; ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINE; CODON; CRANIAL SUTURES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; MALE; MICE; MICE, TRANSGENIC; MUTATION; OSTEOBLASTS; PHENOTYPE; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; PROTEIN BINDING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS;

EID: 84903974347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101693     Document Type: Article

References (46)

1. Jabs EW, Li X, Scott AF, Meyers G, Chen W, et al. (1994) Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet 8: 275-279. (Pubitemid 24338740)
2. Przylepa KA, Paznekas W, Zhang M, Golabi M, Bias W, et al. (1996) Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat Genet 13: 492-494. (Pubitemid 26259929)
3. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, et al. (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 8: 98-103. (Pubitemid 24274068)
4. Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, et al. (1995) Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet 9: 173-176.
5. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, et al. (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9: 165-172.
6. Yu K, Herr AB, Waksman G, Ornitz DM (2000) Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci U S A 97: 14536-14541. (Pubitemid 32016611)
7. Yang F, Wang Y, Zhang Z, Hsu B, Jabs EW, et al. (2008) The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model. Bone 43: 55-63.
8. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, et al. (2004) A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279: 45926-45934. (Pubitemid 39491585)
9. Suzuki H, Suda N, Shiga M, Kobayashi Y, Nakamura M, et al. (2012) Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. J Cell Physiol 227: 3267-3277.
10. Morita J, Nakamura M, Kobayashi Y, Deng CX, Funato N, et al. (2013) Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model. Dev Dyn 243: 560-567.
11. Sasaki Y, Akiyoshi K (2010) Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec 10: 366-376.
12. Shimoda A, Sawada S, Kano A, Maruyama A, Moquin A, et al. (2012) Dual crosslinked hydrogel nanoparticles by nanogel bottom-up method for sustained-release delivery. Colloids Surf B Biointerfaces 99: 38-44.
13. Kageyama S, Kitano S, Hirayama M, Nagata Y, Imai H, et al. (2008) Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 99: 601-607. (Pubitemid 351228580)
14. Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, et al. (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 12: 7397-7405. (Pubitemid 46095414)
15. Shimizu T, Kishida T, Hasegawa U, Ueda Y, Imanishi J, et al. (2008) Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. Biochem Biophys Res Commun 367: 330-335.
16. Watanabe K, Tsuchiya Y, Kawaguchi Y, Sawada S, Ayame H, et al. (2011) The use of cationic nanogels to deliver proteins to myeloma cells and primary T lymphocytes that poorly express heparan sulfate. Biomaterials 32: 5900-5905.
17. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, et al. (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9: 572-578.
18. Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, et al. (2002) Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99: 3717-3724. (Pubitemid 34534543)
19. Fujioka-Kobayashi M, Ota MS, Shimoda A, Nakahama K, Akiyoshi K, et al. (2012) Cholesteryl group- and acryloyl group-bearing pullulan nanogel to deliver BMP2 and FGF18 for bone tissue engineering. Biomaterials 33: 7613-7620.
20. Hayashi C, Hasegawa U, Saita Y, Hemmi H, Hayata T, et al. (2009) Osteoblastic bone formation is induced by using nanogel-crosslinking hydrogel as novel scaffold for bone growth factor. J Cell Physiol 220: 1-7.
21. Trowell OA (1954) A modified technique for organ culture in vitro. Exp Cell Res 6: 246-248.
22. Rice DP, Kim HJ, Thesleff I (1999) Apoptosis in murine calvarial bone and suture development. Eur J Oral Sci 107: 265-275.
23. Chen L, Li D, Li C, Engel A, Deng CX (2003) A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33: 169-178. (Pubitemid 37117129)
24. Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, et al. (2009) Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328: 273-284.
25. Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, et al. (2005) Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development 132: 3537-3548. (Pubitemid 41246127)
26. Lali FV, Hunt AE, Turner SJ, Foxwell BM (2000) The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 275: 7395-7402. (Pubitemid 30146294)
27. Matsumoto K, Nakanishi H, Koizumi Y, Seike T, Tanimoto Y, et al. (2002) Correction of a deformed thumb by distraction of the phalanx. Scand J Plast Reconstr Surg Hand Surg 36: 368-372. (Pubitemid 36061335)
28. Fragale A, Tartaglia M, Bernardini S, Di Stasi AM, Di Rocco C, et al. (1999) Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 154: 1465-1477. (Pubitemid 29226442)
29. Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, et al. (1998) Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 101: 1310-1317. (Pubitemid 28145247)
30. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, et al. (2009) Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem 284: 4897-4904.
31. Behr B, Longaker MT, Quarto N (2013) Absence of endochondral ossification and craniosynostosis in posterior frontal cranial sutures of Axin2(-/-) mice. PLoS One 8: e70240.
32. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP (2009) ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33: 591-601.
33. Miralles F, Czernichow P, Ozaki K, Itoh N, Scharfmann R (1999) Signaling through fibroblast growth factor receptor 2b plays a key role in the development of the exocrine pancreas. Proc Natl Acad Sci U S A 96: 6267-6272. (Pubitemid 29256654)
34. Oldridge M, Zackai EH, McDonald-McGinn DM, Iseki S, Morriss-Kay GM, et al. (1999) De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. Am J Hum Genet 64: 446-461. (Pubitemid 129500527)
35. Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C (2001) A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. Proc Natl Acad Sci U S A 98: 3855-3860. (Pubitemid 32249861)
36. Rice DP, Rice R, Thesleff I (2003) Fgfr mRNA isoforms in craniofacial bone development. Bone 33: 14-27. (Pubitemid 36952684)
37. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, et al. (2000) Integration of FGF and TWIST in calvarial bone and suture development. Development 127: 1845-1855. (Pubitemid 30311788)
38. Veistinen L, Aberg T, Rice DP (2009) Convergent signalling through Fgfr2 regulates divergent craniofacial morphogenesis. J Exp Zool B Mol Dev Evol 312B: 351-360.
39. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, et al. (2012) Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5: ra3.
40. Fong KD, Song HM, Nacamuli RP, Franc BL, Mari C, et al. (2004) Apoptosis in a rodent model of cranial suture fusion: in situ imaging and gene expression analysis. Plast Reconstr Surg 113: 2037-2047. (Pubitemid 39201723)
41. Yin L, Du X, Li C, Xu X, Chen Z, et al. (2008) A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42: 631-643.
42. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX (2007) RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39: 1145-1150. (Pubitemid 47340648)
43. Shen K, Krakora SM, Cunningham M, Singh M, Wang X, et al. (2009) Medical treatment of craniosynostosis: recombinant Noggin inhibits coronal suture closure in the rat craniosynostosis model. Orthod Craniofac Res 12: 254-262.
44. Chevrel G, Garnero P, Miossec P (2002) Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation. Ann Rheum Dis 61: 730-733. (Pubitemid 34787713)
45. Lamoureux F, Picarda G, Rousseau J, Gourden C, Battaglia S, et al. (2008) Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther 7: 3389-3398.
46. Johnson D, Wilkie AO (2011) Craniosynostosis. Eur J Hum Genet 19: 369-376.